DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Phase 2

Completed

Conditions: HIV
HIV/HCV Co-infection
Liver Fibrosis
Hepatitis C

Interventions: Biological: Simtuzumab

First Posted Date: 2012-10-16

Last Posted Date: 2019-11-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 18

Registration Number: NCT01707472

Locations: 🇺🇸
NIH Department of Laboratory Medicine, Bethesda, Maryland, United States

A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

Phase 1

Completed

Conditions: Lymphoid Malignancies

Interventions: Drug: GS-9820

First Posted Date: 2012-10-12

Last Posted Date: 2016-05-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 39

Registration Number: NCT01705847

Locations: 🇳🇱
VU Medical Center (VUmc), Amsterdam, Netherlands
🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱
St. Antonius Hospital, Nieuwegein, Netherlands

and more 1 locations

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome
HIV Infections

Interventions: Drug: E/C/F/TDF
Drug: RTV
Drug: ATV
Drug: ATV Placebo
Drug: FTC/TDF
Drug: RTV Placebo
Drug: FTC/TDF Placebo
Drug: E/C/F/TDF Placebo
Drug: E/C/F/TAF

First Posted Date: 2012-10-12

Last Posted Date: 2019-09-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 583

Registration Number: NCT01705574

Locations: 🇺🇸
Mercer University Mercer Medicine, Macon, Georgia, United States
🇺🇸
Saint Michael's Medical Center, Newark, New Jersey, United States
🇺🇸
New Jersey Medical School, Newark, New Jersey, United States

and more 96 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2012-10-05

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 870

Registration Number: NCT01701401

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Phase 2

Completed

Conditions: Hepatitis C
Cirrhosis
Portal Hypertension
With or Without Liver Decompensation

Interventions: Drug: SOF
Drug: RBV

First Posted Date: 2012-09-18

Last Posted Date: 2016-09-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 50

Registration Number: NCT01687257

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Phase 2

Completed

Conditions: Recurrent Chronic Hepatitis C Virus
Post Liver Transplant

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2012-09-18

Last Posted Date: 2014-12-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 40

Registration Number: NCT01687270

Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Placebo to match SOF
Drug: SOF
Drug: RBV
Drug: Placebo to match RBV

First Posted Date: 2012-09-11

Last Posted Date: 2014-10-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 421

Registration Number: NCT01682720

Locations: 🇩🇪
Centrum fuer interdisziplinaere Medizin Muenster GmbH, Münster, Germany
🇩🇪
Universitatsklinikum, Hamburg, Germany
🇦🇹
Wilhelminenspital, Wien, Austria

and more 74 locations

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Phase 1

Terminated

Conditions: Severe Renal Impairment

Interventions: Drug: RANEXA

First Posted Date: 2012-08-30

Last Posted Date: 2012-12-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 4

Registration Number: NCT01675973

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Phase 2

Terminated

Conditions: Liver Fibrosis Due to NASH

Interventions: Biological: Placebo
Biological: SIM

First Posted Date: 2012-08-27

Last Posted Date: 2019-03-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 259

Registration Number: NCT01672879

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Southern California Liver Centers, Coronado, California, United States
🇺🇸
University of California, San Diego (UCSD), San Diego, California, United States

and more 56 locations

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Liver Fibrosis Due to NASH

Interventions: Biological: SIM
Biological: Placebo

First Posted Date: 2012-08-27

Last Posted Date: 2019-03-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 222

Registration Number: NCT01672866

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 65 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy